GlassScriptPhysician profile
Marrick Kukin
NPI 1609869551
$17,248.28
in general payments reported to CMS, 2019-2025
17 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.16 · 2021: $12.58 · 2022: $1,381 · 2023: $15K · 2024: $365 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,115.00 |
| Food and Beverage | $725.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $16,015.00 | 2022-2023 | Sentus, Solia, Acticor 7 Vr-T Dx |
| Merck Sharp & Dohme LLC | $282.39 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.31 | 2022-2024 | Jardiance |
| Baxter Healthcare | $137.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $134.77 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $90.23 | 2019-2024 | |
| Cvrx, INC. | $85.12 | 2022-2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $75.48 | 2022-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $72.53 | 2022-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $43.01 | 2022-2024 | Eliquis |
| Irhythm Technologies, INC. | $41.12 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $38.46 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.01 | 2021-2023 | Lifevest |
| Abbott Laboratories | $19.91 | 2023 | Cardiomems |
| Novo Nordisk INC | $18.84 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.65 | 2022 | |
| Pfizer INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marrick Kukin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.